Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: Nav1.7 voltage-gated sodium channel inhibitors - SiteOne Therapeutics

Drug Profile

Research programme: Nav1.7 voltage-gated sodium channel inhibitors - SiteOne Therapeutics

Alternative Names: GTX analogues - SiteOne Therapeutics; Guanidinium toxin analogues - SiteOne Therapeutics; NaV1.7 inhibitors - SiteOne Therapeutics; Selective NaV1.7 channel blockers - SiteOne Therapeutics; Sodium ion channel 1.7 inhibitors - OneSite Therapeutics; ST Oral; ST SubQ; ST Topical; ST-2578

Latest Information Update: 28 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Stanford University
  • Developer SiteOne Therapeutics
  • Class Analgesics; Antipruritics; Diagnostic agents; Imaging agents; Muscle relaxants; Small molecules
  • Mechanism of Action Nav1.7 voltage-gated sodium channel inhibitors; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer; Muscle hypertonia; Pain; Postoperative pain; Pruritus

Most Recent Events

  • 28 Nov 2022 No recent reports of development identified for preclinical development in Postoperative-pain in USA (IV, Injection)
  • 28 Oct 2022 No recent reports of development identified for research development in Pain in USA (SC)
  • 28 Apr 2022 No recent reports of development identified for preclinical development in Pain in USA (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top